Viatris Expects its First Interchangeable Designation for Insulin Products
Shots:
- Viatris reported that its insulin glargine and insulin aspart products are both on track to be approved by the FDA as interchangeable by July 2021
- The biosimilars are the proposed biosimilars of Sanofi’s Lantus and Novo Nordisk’s Novolog/Novorapid products respectively
- If approved- Viatris’s insulin products would be the first biosimilars to receive the US FDA’s interchangeable designations
Ref: Viatris | Image: Viatris
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com